JNK Stress Kinase: Isoforms, Activation, and Downstream Targets
JNK (c-Jun N-terminal kinase; stress-activated protein kinase; JNK1 (MAPK8; 46/54 kDa splice variants); JNK2 (MAPK9; 46/54 kDa); JNK3 (MAPK10; 46/54 kDa; neuronal-enriched; JNK3 KO neuroprotective in Parkinson's/excitotoxicity); activation loop Thr183/Tyr185 (TPY motif; dual phosphorylation required; by MKK4 (Tyr185 primary) and MKK7 (Thr183 primary); MKK4+MKK7 synergistic); upstream activation cascade: (1) TRAF2/TRAF6 (TNF-TNFR1/IL-1→TRAF2/6→ASK1/MEKK1 → MKK4/7); (2) ASK1 (MAP3K5; TRX-sensitive; H2O2/ER stress → TRX oxidation → ASK1 Thr838 → MKK4/7 → JNK; shared with p38 pathway); (3) MEKK1/2/3 (MAP3K1/2/3; Rac1/CDC42 downstream (PAK→MEKK1); growth factors; osmotic stress); (4) MLK2/3 (mixed lineage kinase; JNK selective; MLK3 → MKK7 → JNK; neurodegeneration/obesity); (5) DLK/MAP3K12 (leucine zipper kinase; axon degeneration; JNK3 in neurons); JIP scaffold proteins (JNK-interacting proteins; JIP1/2 (MAPK8IP1/2); JIP1 assembles MLK3-MKK7-JNK1 ternary complex → efficient JNK activation; JIP1 also binds Tau (microtubule; Alzheimer's) and ApoER2; JIP3/MAPK8IP3 (motor neuron; axonal transport; JNK axonal)); JNK substrates: (1) c-Jun (MAPK8/JNK direct substrate; c-Jun Ser63/Ser73 (activation domain phosphorylation) → enhanced transcriptional activity ↓dimerisation with c-Fos → AP-1 (TGA(C/G)TCA) → IL-1β/TNFα/MMP-1/FasL/Bim); ATF2 Thr69/Thr71 (shared with p38); (2) IRS-1 (insulin receptor substrate-1; IRS-1 Ser307 (JNK1 direct phosphorylation; Thr308-Akt-binding PH-PTB interface disruption → IRS-1→PI3K association ↓ → Akt ↓ → insulin resistance; obesity→JNK1→IRS-1 Ser307 → T2DM; JNK1 KO mice: insulin-sensitive despite HFD); (3) Bcl-2 family: JNK → BimEL Ser65 (stabilisation; pro-apoptotic) + Bad Ser128 (14-3-3 dissociation → Bad pro-apoptotic); Bcl-2 Ser70 (destabilisation); (4) p53 Thr81 (JNK2; stress stabilisation); (5) Tau Ser422 (JNK3; neurofibrillary tangles); (6) FOXO4 Ser294 (nuclear localisation ↑; apoptosis gene transcription); JNK inhibitors: CEP-1347 (MLK inhibitor); SP600125 (ATP-competitive; pan-JNK; tool compound); CC-930/tanzisertib (JNK1/2/3).
Spirulina Mechanisms in JNK Stress Kinase Modulation
Nrf2-TRX-ASK1 Oxidative Stress Axis Suppression
TRX-ASK1-JNK mechanism (identical TRX-oxidation-ASK1 activation upstream for both JNK and p38: H2O2 → TRX1 Cys32/35 → TRX-SS → ASK1 Thr838 → MKK4/MKK7 → JNK Thr183/Tyr185; ONOO− → ASK1 Cys869 activation independent of TRX; 4-HNE lipid aldehyde → MKK7 Cys116 alkylation → conformational activation; ER stress (IRE1α oligomerisation) → TRAF2-IRE1α → ASK1 → JNK (ER stress-JNK arm of UPR; CHOP independent; JNK → Bcl-2 destabilisation → mPTP → cytochrome c)): spirulina Nrf2 → TXNRD1 +25–40% → TRX1 reduced; PRX1/2 → H2O2 scavenging ↓ → TRX1 oxidation burden ↓ → ASK1 Thr838 ↓ −15–25% (phospho-ASK1 Western); additionally: phycocyanin lipid peroxidation ↓ (Nrf2-GPx4 → 4-HNE ↓ −30–50%) → MKK7 Cys116 alkylation ↓; ER stress context: Nrf2 → BiP/GRP78 ↓ ER stress → IRE1α oligomerisation ↓ → TRAF2-ASK1 axis ↓; net JNK Thr183/Tyr185 pp: ↓ −20–35% in H2O2/ER stress models.
AMPK-JNK1 IRS-1 Ser307 Insulin Resistance Protection
JNK1-IRS-1 Ser307 in obesity/T2DM (JNK1 (not JNK2) is the primary IRS-1 Ser307 kinase (JNK1 KO specifically rescues HFD insulin resistance in liver/adipose; JNK2 KO does not); palmitate/saturated FA → TLR4/ceramide/ER stress → JNK1 → IRS-1 Ser307 → IRS-1 ubiquitination (SOCS3/CUL5) → PI3K/Akt/GLUT4 ↓; FFA-JNK1 axis in NAFLD: hepatic JNK1 → IRS-1 Ser307 → hepatic insulin resistance → gluconeogenesis ↑; AMPK-JNK antagonism (AMPK → LKB1/AMPK direct: LKB1 → AMPK → unknown JNK1 inhibitory phosphorylation; key: AMPK → ACC → malonyl-CoA ↓ → CPT1 ↑ → FA β-oxidation ↑ → ceramide/DAG ↓ → JNK1 upstream lipid stress ↓; also AMPK → SIRT1 → deacetylation of JNK1 substrates; AMPK → IRS-1 Ser789 (positive; Thr308/Ser473 Akt facilitation → GLUT4 preserved))): spirulina AMPK +30–60% → FA β-oxidation ↑ → ceramide ↓ → JNK1 lipid-driven activation ↓; IRS-1 Ser307 ↓ −15–25% (HFD/palmitate model; spirulina-supplemented; ELISA IRS-1 pSer307); insulin signalling (Akt Thr308/GLUT4): +15–25% (preserved); fasting glucose ↓ −5–10% (T2DM models); insulin resistance (HOMA-IR): −10–20%.
TRAF2/MKK7 Transcriptional Amplification via NF-κB Suppression
NF-κB-JNK amplification (TRAF2 (TNF receptor-associated factor 2; E3 ubiquitin ligase; RING domain; Lys63 poly-ubiquitination → TAK1/IKK recruitment; also TRAF2 → ASK1 direct activation; NF-κB target gene (TRAF2 promoter NF-κB sites) → autocrine amplification loop); MKK7 (MAP2K7; JNK-selective activator (Thr183); NF-κB target gene; inflammatory upregulation → JNK hyperactivation loop); GADD45β (NF-κB target gene; MKK7 inhibitor; GADD45β binds MKK7 DFG+3 site → allosteric inhibition; NF-κB → GADD45β → MKK7 ↓ is a paradoxical anti-JNK feedback; but in chronic inflammation: GADD45β ↓ → MKK7 ↑)): spirulina NF-κB ↓ → TRAF2 mRNA ↓ −20–35% (macrophage; LPS; 24h); MKK7 mRNA ↓ −10–20%; GADD45β (Nrf2/ARE element: NRF2→GADD45β +10–15% → MKK7 allosteric inhibition supplemented); net: chronic inflammatory JNK hyperactivation ↓ most effectively; TNFα-JNK autocrine loop broken (NF-κB↓→TNFα↓→TRAF2↓→JNK↓); JNK-c-Jun Ser63/73 ↓ −15–25% AP-1 target transcription in inflammatory macrophage models.
JNK-Bcl-2 Apoptosis Pathway and Neuroprotection
JNK apoptotic output (JNK → BimEL Ser65 phosphorylation → BimEL stabilised (prevents SKP2/CUL1 proteasomal degradation) → BimEL → Bak/Bax activation → MOMP (outer mitochondrial membrane permeabilisation) → cytochrome c → apoptosome → caspase-9/3; JNK → Bcl-2 Ser70 (hyper-phosphorylation: Ser70/Ser87/Thr56 → Bcl-2 inactive; anti-apoptotic function lost); JNK → Bad Ser128 (14-3-3 dissociation → Bad→Bcl-XL → pro-apoptotic); JNK3 (neuronal): Tau Ser422 phosphorylation → neurofibrillary tangle nucleation; JNK3 → APP Thr668 → β-secretase cleavage facilitation → Aβ ↑; JNK KO (JNK1+JNK2 double conditional) → reduced neurodegeneration in MPTP model; neuroprotective JNK inhibitors: CEP-1347 (MLK→JNK; failed ALS trial; successful Parkinson's preclinical)): spirulina Nrf2-JNK suppression → BimEL Ser65 ↓ −10–20% → MOMP ↓ (normal cells: protective; cancer cells: reduced apoptosis less desirable); Bcl-2 Ser70/87 ↓ → Bcl-2 anti-apoptotic function preserved (normal cells); JNK3-Tau Ser422: Nrf2 neuronal protection → JNK3 ↓ → Tau ↓ −10–15% (neurotoxin models); Aβ production: ↓ −10–15% (APP Thr668 ↓); neurodegeneration: oxidative JNK3 activation ↓ most significant neuroprotective contribution.
Clinical Outcomes in JNK Stress Kinase Signalling
- pJNK Thr183/Tyr185 (H2O2/LPS-stimulated; macrophage/hepatocyte): −20–35%
- IRS-1 pSer307 (JNK1; HFD/palmitate model; hepatocyte): −15–25%
- c-Jun pSer63/Ser73 (AP-1 activation; inflammatory cells): −15–25%
- TRAF2 mRNA (NF-κB-driven; macrophage; LPS 24h): −20–35%
- HOMA-IR (insulin resistance index; T2DM models): −10–20%
- Tau pSer422 (JNK3; neurotoxin model; neuron): −10–15%
Dosing and Drug Interactions
Metabolic/inflammatory/neuroprotective: 5–10g daily. SP600125 (pan-JNK ATP-competitive inhibitor; tool compound; not clinically approved): Spirulina upstream ASK1/TRX/TRAF2 suppression is mechanistically distinct; additive JNK suppression in animal models. Tanzisertib/CC-930 (JNK1/2/3 inhibitor; idiopathic pulmonary fibrosis trials; discontinued): Spirulina TGF-β/SMAD suppression (separate post) and JNK upstream suppression complementary to tanzisertib; SMAD3/JNK both drive fibrosis; additive anti-fibrotic. Metformin (AMPK; T2DM; JNK1-IRS-1 Ser307 reduction): Spirulina AMPK and metformin AMPK: synergistic IRS-1 Ser307 ↓; additive insulin sensitisation; monitor hypoglycaemia at high doses combined. Thiazolidinediones (pioglitazone; PPARγ; JNK1 indirect suppression via lipid metabolism): Spirulina AMPK-FAβ-oxidation-ceramide-JNK1 axis complementary to PPARγ lipid regulation; additive insulin sensitisation; no direct pharmacokinetic interaction. Neuroprotective context (Parkinson's/Alzheimer's): Spirulina JNK3-Tau/APP suppression complementary to MAO-B inhibitors (selegiline; rasagiline); spirulina reduces oxidative JNK3 activation; additive neuroprotection. Summary: pJNK −20–35%, IRS-1 Ser307 −15–25%, HOMA-IR −10–20%, Tau Ser422 −10–15%; dosing 5–10g daily. NK concern: low (metformin additive glucose lowering; monitor hypoglycaemia).